Loading company…
QuantX Biosciences discovers oral small molecule drugs for immunology and inflammation.
QuantX Biosciences uses a computational platform to develop oral small molecule therapies for immunology and inflammation, including STAT6 and IL-17 candidates. Founded in 2022 and based in Princeton, US, the company raised USD 85.00 mn in Series B funding on February 9, 2026, with Lilly Asia Ventures and Sanofi Ventures among the investors.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in